European Commission adopts the Mounjaro sleep apnea labeling variation

The European Commission adopted a labeling variation for Mounjaro (tirzepatide) on February 14, 2025, formally updating the medicine's official European product information to reflect a new use: treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity ^[1]. The change, tracked as variation II/0027, updated sections 4.1, 4.8 and 5.1 of the Summary of Product Characteristics (SmPC), which cover the approved indication, side effects, and clinical trial data, along with the accompanying patient package leaflet ^[1].

The update was based on final results from two studies referred to in the regulatory filing as IBF-MC-GPI1 and IBF-MC-GPI2, described as multicentre, randomized, parallel-arm, double-blind, placebo-controlled trials comparing tirzepatide with placebo in adults who had moderate-to-severe OSA and obesity ^[1]. The scientific opinion supporting the change was issued on December 12, 2024, and the Commission Decision formally adopting it followed just over two months later, on February 14, 2025 ^[1]. The regulatory category for the change was listed as "C.I.6.a — Addition of a new therapeutic indication or modification of an approved one," confirming that OSA is now a recognized use for Mounjaro under European Union rules ^[1].

This is one of many changes tracked in Mounjaro's European procedural history. The same document shows Mounjaro's label has been revised repeatedly since its original approval, including a 2023 extension adding chronic weight management for adults with obesity or overweight with a weight-related condition, based on the SURMOUNT-1 trial and five supporting SURPASS studies in people with type 2 diabetes ^[1]. More recently, in a separate filing (II/0038), the manufacturer submitted final results from a trial called SUMMIT, a placebo-controlled study of tirzepatide in people with heart failure with preserved ejection fraction (HFpEF) and obesity; that update has an anticipated decision date of January 29, 2026, according to the same procedural table ^[1].

Why it matters for patients

This decision is a European Union regulatory action, not an action by the U.S. Food and Drug Administration. It changes what Mounjaro's official label says can be treated in EU member states, based on the two placebo-controlled OSA trials cited in the filing ^[1]. The source document does not include efficacy numbers, such as how much OSA severity improved, nor does it describe side effects observed in the trials beyond noting that section 4.8 (adverse reactions) was updated ^[1]. Patients in the United States taking tirzepatide products should know that European label changes do not automatically apply to U.S. prescribing information, and this filing does not address the U.S. regulatory status of tirzepatide for sleep apnea. It is not yet known from this document how, or whether, this EU labeling update will affect access, coverage, or prescribing practices for tirzepatide-based OSA treatment outside Europe.

For readers tracking safety data, the presence of this update alongside years of manufacturing, quality-control, and periodic safety update filings reflects the routine, ongoing regulatory oversight that accompanies a widely used medicine, rather than a single new safety signal ^[1].

What happens next

According to the procedural document, the next scheduled Mounjaro label update tied to major trial results is the HFpEF-related SUMMIT trial change, with an anticipated decision date of January 29, 2026 ^[1]. A related notification affecting labeling and the package leaflet was also logged with a decision date of January 22, 2026 ^[1]. Beyond these dated entries, the source does not specify further planned changes to the OSA indication itself.